Unique ID issued by UMIN | UMIN000012948 |
---|---|
Receipt number | R000015133 |
Scientific Title | Phase II randomized study to investigate the effectiveness of Hangeshashinto(TJ-14) against chemoradiation-induced oral and pharyngeal mucositis |
Date of disclosure of the study information | 2014/01/24 |
Last modified on | 2014/01/24 17:58:50 |
Phase II randomized study to investigate the effectiveness of Hangeshashinto(TJ-14) against chemoradiation-induced oral and pharyngeal mucositis
A rondomized study to investigate the effectiveness of Hangeshashinto(TJ-14) against chemoradiation-induced oral mucositis
Phase II randomized study to investigate the effectiveness of Hangeshashinto(TJ-14) against chemoradiation-induced oral and pharyngeal mucositis
A rondomized study to investigate the effectiveness of Hangeshashinto(TJ-14) against chemoradiation-induced oral mucositis
Japan |
head and neck cancer
Oto-rhino-laryngology |
Malignancy
NO
To investigate the preventive effect of Hangeshashinto(TJ-14) for chemoradiation-induced mucositis in head and neck cancer patients
Efficacy
Exploratory
Phase II
Incidence of more than grade 3 oral mucositis by CTCAE Ver. 4.0
1) Rates of chemoradiation completion
2) Duration of presence of more than grade 3 oral mucositis
3) Days until incidence of more than grade 3 oral mucositis
4) Total dose of opioids
5) Change of body weight
6) Nutrition status
7) Use of tube feeding
8) Grade of Dry mouth by CTCAE version 4.0 more than 6 months after chemoradiation
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
Numbered container method
2
Treatment
Medicine |
Administration of Hangeshashinto(TJ-14) during chemoradiation for more than 6 weeks other than basic supportive cares for oral mucositis.
Only basic supportive cares for oral mucositis.
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Stage II-IVB oral, pharyngeal or laryngeal patients.
2) Patients who undergo chemoradiatio with cisplatin of more than 60 Gy for whole neck.
3) Patients who can take Hangeshashinto (TJ-14) by mouth.
4) Performance status 0 or 1.
5) Patients meeting all crietia below in the laboratory data within 7 days before starting chemoradiation.
WBC; more than 4,000/mm3,
Neutrophil count; more than 1,500/mm3
Platelet count; more than 100,000/mm3
BUN, ALT, AST; less than facility criteria
Creatinin clearance or correction eGFR
;less than 60ml/min
6) Inpatients.
1) Patients administered other Kampo medicine within 2 weeks before registration
2) Patients who were continuously adminisiterd NSAIDs, opioids or steroids within one month before registration
3) Patients having serious comorbid disease
4) Patients administered a developing new drug
5) Pregnant patients
90
1st name | |
Middle name | |
Last name | Akihiro Shiotani |
National Defense Medical College of Japan
Department of Otolaryngolory-Head and Neck Surgery
3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
+81-4-2995-1686
ashiotan@ndmc.ac.jp
1st name | |
Middle name | |
Last name | Taku Yamashita |
National Defense Medical College of Japan
Department of Otolaryngolory-Head and Neck Surgery
3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
+81-4-2995-1686
tkym@ndmc.ac.jp
Department of Otolaryngolory-Head and Neck Surgery, National Defense Medical College of Japan
Department of Otolaryngolory-Head and Neck Surgery, National Defense Medical College of Japan
Self funding
NO
防衛医科大学校病院(埼玉県)、神奈川県警友会けいゆう病院(神奈川県)、済生会宇都宮病院(栃木県)、さいたま市立病院(埼玉県)、佐野厚生総合病院(栃木県)、独立行政法人国立病院機構栃木医療センター(栃木県)、横浜市立市民病院(神奈川県)
2014 | Year | 01 | Month | 24 | Day |
Unpublished
Open public recruiting
2014 | Year | 01 | Month | 22 | Day |
2014 | Year | 01 | Month | 24 | Day |
2014 | Year | 01 | Month | 24 | Day |
2014 | Year | 01 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015133